Di Dong-Xue, Ai Qi, Yan Qi, Li Yan, Zhang Hong-Mei, Chen Ling, Tang Xin-Ning
The First Department of Bone and Joint, Wangjing Hospital, Chinese Academy of Chinese Medical Sciences, Beijing 100102.
Zhongguo Gu Shang. 2023 Jul 25;36(7):647-53. doi: 10.12200/j.issn.1003-0034.2023.07.010.
To investigate the effect of Bushen Chushi decoction combined with platelet-rich plasma(PRP) to treat knee osteoarthritis(KOA) in early and middle stage and its regulation on TGF-β1 and Smad-1 expression in serum.
Total of 45 patients with KOA in early and middle stage from May 2020 to April 2022 were treated and divided into control group and observation group. In control group, there were 30 patients including 12 males and 18 females, aged from 43 to 69 years old with an average of(57.3±6.5) years old and disease duration ranged from 1.5 to 5.0 years with an average of(3.8±1.7) years, and there were 8 cases in gradeⅠ, 13 cases in gradeⅡ, and 9 cases in grade Ⅲ according to Kellgren-Lawrence Grade, PRP 5 ml was injected into knee joint on the first day of No1, 3 week together for 2 times. In the observation group, there were 15 cases including 7 males and 8 females, aged from 45 to 70 years old with an average of (56.7±6.2) years old and disease duration ranged from 1.8 to 5.7 years with an average of (4.0±1.8) years, there were 4 cases in gradeⅠ, 9 cases in gradeⅡand 4 cases in grade Ⅲ according to the Kellgren-Lawrence Grade, PRP 5 ml were injected into knee joints that the time and frequency were the same as those in the control group, and at the same time Bushen Chushi decoction orally were taken 1 dose per day with a total of 28 doses. All patients were treated for four weeks. Visual analogue scale(VAS) and Lequesne MG score before and after treatment were used to evaluate improvement of knee pain and joint function. The TGF-β1 and Smad-1 levels in serum were measured before and after treatment in two groups. The incidence of complications in two groups was observed.
All patients were followed up for 26 to 30 days with an average of (28.0±0.6) days. There was no significant difference in VAS and knee Lequesne MG scores between two groups before treatment(>0.05). The scores of VAS and knee Lequesne MG on the first day after treatment in both groups were lower than those before treatment(<0.05). The VAS and knee Lequesne MG scores in observation group were lower than those in control group(<0.05) on the first day after treatment. The TGF-β1 level in serum after treatment were higher significantly than that before treatment in two groups(<0.05). After treatment, TGF-β1 level in serum in observation group were lower than those in control group with statistically significant differences(<0.05). The Smad-1 levels in serum after treatment in observation group were higher significantly than that in control group(<0.05). The levels of Smad-1 were not statistically significant between before and after treatment(>0.05). There was no significant difference in postopertaive complications between two groups (>0.05).
The efficacy of Bushen Chushi decoction combined with PRP in treatment of early and middle KOA is better than that of PRP injection alone. The combined treatment could reduce TGF-β1 level and increase Smad-1 level in serum, which may be a mechanism to inhibit inflammation and alleviate cartilage degeneration to some extent.
探讨补肾除湿汤联合富血小板血浆(PRP)治疗早中期膝关节骨性关节炎(KOA)的疗效及其对血清中转化生长因子-β1(TGF-β1)和Smad-1表达的调控作用。
选取2020年5月至2022年4月收治的45例早中期KOA患者,分为对照组和观察组。对照组30例,男12例,女18例,年龄43~69岁,平均(57.3±6.5)岁,病程1.5~5.0年,平均(3.8±1.7)年,根据Kellgren-Lawrence分级,Ⅰ级8例,Ⅱ级13例,Ⅲ级9例,于第1、3周第1天膝关节腔内注射PRP 5 ml,共2次。观察组15例,男7例,女8例,年龄45~70岁,平均(56.7±6.2)岁,病程1.8~5.7年,平均(4.0±1.8)年,根据Kellgren-Lawrence分级,Ⅰ级4例,Ⅱ级9例,Ⅲ级4例,膝关节腔内注射PRP 5 ml的时间和频率同对照组,同时口服补肾除湿汤,每日1剂,共28剂。所有患者均治疗4周。采用视觉模拟评分法(VAS)和Lequesne MG评分评估治疗前后膝关节疼痛及关节功能改善情况。检测两组治疗前后血清中TGF-β1和Smad-1水平。观察两组并发症发生情况。
所有患者随访26~30天,平均(28.0±0.6)天。治疗前两组VAS及膝关节Lequesne MG评分比较,差异无统计学意义(>0.05)。两组治疗后第1天VAS及膝关节Lequesne MG评分均低于治疗前(<0.05)。治疗后第1天观察组VAS及膝关节Lequesne MG评分低于对照组(<0.05)。两组治疗后血清TGF-β1水平均较治疗前显著升高(<0.05)。治疗后观察组血清TGF-β1水平低于对照组,差异有统计学意义(<0.05)。治疗后观察组血清Smad-1水平高于对照组(<0.05)。治疗前后Smad-1水平比较,差异无统计学意义(>0.05)。两组术后并发症发生率比较,差异无统计学意义(>0.05)。
补肾除湿汤联合PRP治疗早中期KOA的疗效优于单纯PRP注射。联合治疗可降低血清TGF-β1水平,提高Smad-1水平,这可能是其抑制炎症、在一定程度上减轻软骨退变的机制之一。